Rivastigmine BA Trial With Multiple Application of Transdermal Patches, Adaptation and Tapering Phase
Status:
Completed
Trial end date:
2018-07-05
Target enrollment:
Participant gender:
Summary
The present clinical trial will be conducted to compare the bioavailability of rivastigmine
and assess bioequivalence at steady-state of the Test product RIV-TDS 13.3 mg/24 h and the
marketed Reference product Exelon® 13.3 mg/24 hours transdermal patch after multiple patch
application. Each of both treatments will last 5 days.